| Literature DB >> 31662780 |
Xiaowei Zhou1, Ying Li1, Mingyu Zhang1, Junjie Hao2, Qiong Gu1, Haiyang Liu3, Wei Chen1, Yafei Shi1, Bin Dong1, Yuanyuan Zhang1, Chunyu Li1, Guohui Li1.
Abstract
Nowadays, an increasing number of patients are seriously affected by lung cancer. Si Jun Zi Tang (SJZ), a four-herb Chinese medicine formula first described approximately one thousand years ago, is often prescribed for cancer patients as a complementary therapy. But the research on the effective materials for treating cancer using SJZ was rarely reported. To solve this problem, we evaluate the inhibitory effect of 10 samples of SJZ from different origins on PC9 cells. Ultraperformance liquid chromatography (UPLC) and hierarchical cluster analysis (HCA) along with canonical correlation analysis (CCA) and bioactivity validation were used to investigate the underlying correlation between the chemical ingredients and the antiproliferative effect of SJZ on PC9 cells. The evaluation indicated that 10 batches of SJZ could inhibit proliferation of PC9 cells and there was a notable difference in pharmacological activity between the different SJZ samples. The results of CCA and multivariate statistical analysis indicated that ginsenoside Ro and ginsenoside Rg1 might be active constituents of the antiproliferative effect as determined by spectrum-effect relationships. The results showed that bioassay and spectrum-effect relationships are suitable to associate sample quality with the active ingredient associated with clinical efficacy. And our finding would provide foundation and further understanding of the quality evaluation of traditional Chinese medicine decoction.Entities:
Year: 2019 PMID: 31662780 PMCID: PMC6778903 DOI: 10.1155/2019/7282681
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Inhibitory effects of ten batches of SJZ on PC9 cells. SJZ1-10 (a–j); IC50 of SJZ1-10 on PC9 cells (k).
Figure 2UPLC chromatogram of reference substances (a), test samples (b), and ten batches of SJZ (c). Nine peaks were identified by comparison with standard substances: (a) liquiritin; (b) ginsenoside Rg1, (c) Re, (d) Rb1, (e) Rc, (f) Ro, and (g) Rd; (h) ammonium glycyrrhetate; (i) atractylenolide III.
The relative peak area of nine common peaks measured by UPLC.
| Sample | Peak area of each compound | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| a | b | c | d | e | f | g | h | i | |
| S1 | 71 | 2499 | 548 | 344 | 606 | 839 | 480 | 2971 | 358 |
| S2 | 683 | 1421 | 623 | 1306 | 1189 | 1124 | 384 | 3568 | 391 |
| S3 | 25039 | 1769 | 741 | 2129 | 819 | 664 | 764 | 2523 | 293 |
| S4 | 11207 | 809 | 818 | 602 | 792 | 682 | 591 | 2100 | 604 |
| S5 | 20198 | 964 | 729 | 818 | 705 | 899 | 757 | 3657 | 508 |
| S6 | 11626 | 772 | 638 | 531 | 569 | 507 | 535 | 1285 | 135 |
| S7 | 30946 | 740 | 2396 | 1085 | 938 | 1821 | 622 | 2638 | 239 |
| S8 | 12341 | 723 | 544 | 391 | 403 | 489 | 666 | 1262 | 361 |
| S9 | 12421 | 1161 | 1597 | 1234 | 1363 | 1256 | 1457 | 3885 | 293 |
| S10 | 13951 | 577 | 576 | 1281 | 612 | 392 | 516 | 2465 | 209 |
| RSD% | 69.65 | 52.53 | 65.53 | 56.45 | 36.79 | 50.13 | 44.11 | 34.92 | 41 |
RSD = σ/μ ∗ 100; RSD is the relative standard deviation; σ is the standard deviation; μ is the average value of peak area.
Figure 3HCA heat map for ten SJZ samples and nine chemical compounds (right of the map).
Figure 4Analysis of the spectrum-effect relationship: (a) the correlation coefficient between the content of chemical compounds and bioactivity; (b) thermograph of the correlation analysis of all factors. (1) Ginsenoside Re; (2) ginsenoside Ro; (3) ginsenoside Rg1; (4) atractylenolide III; (5) ginsenoside Rc; (6) ginsenoside Rd; (7) ginsenoside Rb1; (8) ammonium glycyrrhetate; (9) liquiritin; (10) IC50. p < 0.01.
Figure 5Dose-response curves of eight constituents inhibiting PC9 cell proliferation. (1) Ginsenoside Re; (2) ginsenoside Ro; (3) ginsenoside Rg1; (4) atractylenolide III; (5) ginsenoside Rc; (6) ginsenoside Rd; (7) ginsenoside Rb1; (8) ammonium glycyrrhetate.